Northwestern University

May
28
Tue 3:30 PM

INVO & Lakeside Discovery Seminar | Transforming Antibodies into Drugs

When: Tuesday, May 28, 2019
3:30 PM - 6:00 PM  

Where: Prentice Women's, 3rd Floor, L North Conference Room, 250 E Superior St, Chicago, IL

Audience: Faculty/Staff - Post Docs/Docs - Graduate Students

Contact: Sonia Kim   847.467.0446

Group: Innovation and New Ventures Office

Category: Lectures & Meetings

Description:

Please join INVO and Lakeside Discovery for this May seminar which aims to provide insight into antibody therapeutic discovery and development in the academic setting. Experts will examine the state-of-the-art science in the field and provide details on resources available at Northwestern to accelerate antibody discovery.

Over the past 5 years, recombinant antibodies have been established at a growing rate into clinical practice for the treatment of diseases ranging from cancer to autoimmune and infectious diseases. The seminar will cover various aspects related to the commercialization of therapeutic antibodies, with the hope of fostering PI interest in future submissions to Lakeside Discovery, a drug discovery collaboration between Northwestern University and Deerfield Management.

3:30pm Welcome and Introductions
3:35pm Lakeside Discovery – Transforming Discoveries into Drugs
4:00pm Current and Future Trends in Therapeutic Antibodies
4:30pm Q&A Session
5-6:00pm Reception

OUR SPEAKERS

William Slattery
Partner, Deerfield Management
Joint Steering Committee Member, Lakeside Discovery

Mr. Slattery is a Partner on the Biotherapeutics group at Deerfield, which he joined in 2000. He began his professional career studying immune system complications associated with End Stage Renal Disease. Prior to joining Deerfield, Mr. Slattery was a senior healthcare analyst between 1990 and 2000 at Amerindo Investment Advisors overseeing biotechnology investments. He has held various positions in research including those at National Medical Enterprises, Johnson & Johnson, and HMSS. Mr. Slattery is the Chairman of Gilda’s Club New York City, a non-profit organization supporting cancer patients and their families. Mr. Slattery has a degree in Biology and Chemistry from State University of New York at Albany and completed coursework in Immunology at the Graduate School-New Brunswick, Rutgers University.


Larry Green, Ph.D.
Founder and CEO, Ablexis
Co-inventor, AlivaMab Mouse
CEO, AlivaMab Discovery Services

Larry is CEO and founder of Ablexis, and co-inventor of the AlivaMab Mouse. He also serves as CEO of AlivaMab Discovery Services. Larry has over a quarter century of experience in designing, creating and using transgenic mouse platforms for antibody drug discovery. Larry joined Aliva Biopharmaceuticals, Inc. in 2008 as CEO, where he optimized the blueprint for AlivaMab Mouse and procured a Series A financing, resulting in the founding of Ablexis, LLC in 2009. Prior to joining Aliva, he was a co-inventor of the XenoMouse® technology at Cell Genesys and was a scientific founder of the spin-out of Abgenix, where he served as designer and team leader for making improved versions of the XenoMouse® technology, director of antibody discovery operations, leader of the collaborations group, and the senior research representative on joint steering committees in alliances with Amgen, AstraZeneca, Pfizer amongst other companies.

Larry is an inventor on several dozen patents covering immunoglobulin transgenic mice and therapeutic antibodies. He received his Ph.D. in Molecular and Cellular Biology from the University of Wisconsin-Madison and did postdoctoral research at the University of Colorado at Boulder and Stanford University.


Joseph Pearlberg, M.D., Ph.D.
Vice President of Scientific Affairs, Deerfield Management
Joint Steering Committee Member, Lakeside Discovery

Dr. Pearlberg is the Vice President of Scientific Affairs and is on the Biotherapeutics group at Deerfield which he joined in July 2017. Prior to joining Deerfield, he was the Vice President of Clinical Development at Infinity Pharmaceuticals from December 2015 until July 2017. Prior to Infinity Pharmaceuticals, Dr. Pearlberg worked as a Medical Director in the oncology unit of Sanofi from November 2010 until September 2014. Dr. Pearlberg received his M.D. at the University of California, San Francisco, and completed his clinical training at the Massachusetts General Hospital and Dana Farber Cancer Institute. Dr. Pearlberg also received his Ph.D. in molecular biology from Harvard University and was a Lecturer in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He also holds a B.A. in Biochemistry from the University of Pennsylvania.


Amie Phinney, Ph.D., M.B.A.
Director of Alliance Management, Lakeside Discovery

Amie joined Lakeside Discovery in August 2018. Amie brings extensive experience in drug discovery, preclinical development and alliance management. Amie began her pharmaceutical career as a Senior Scientist, Preclinical Project Director and Program Manager in the Neuroscience Division of Solvay Pharmaceutical in the Netherlands. Later at Abbott Labs and AbbVie Pharmaceuticals, Amie continued to develop her expertise in the development of drug candidates, specializing in partnered discovery projects. In her roles as a Collaboration Project Manager, Operations Director and Alliance Leader, Amie successfully led multi-party, cross-functional project teams through all stages of drug discovery. Before joining industry, Amie was a research fellow at the University of Toronto and the Free University of Amsterdam. She holds a PhD in Biomedical Research from the University of Basel in Switzerland and an MBA from Lake Forest Graduate School of Management in Illinois.

Register Add Event to Calendar

Add Event To My Group:

Please sign-in